Phase II Trial to Evaluate Immune-related Biomarkers for Pathological Response in Stage II-III HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy with Subsequent Randomization to Multi-epitope HER2 Vaccine vs. Placebo in Patients with Residual Disease Post-neoadjuvant Chemotherapy

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery»